This POV breaks down new deliverability rules from ISPs and shares how marketers can protect inbox placement while building trust and improving performance.

Daeyoung Kang

Claire Howard

Deliverability is an Evergreen Strategy

It’s time to consider how the hidden burden of time toxicity shapes cancer care. Explore why addressing it can unlock better outcomes, equity, and a positive brand experience.


Dane Lund

Jorge Durand

Emerging Trends: Time Toxicity in Oncology

Oncology engagement is evolving. Learn how AI, real-world data, and digital behaviors are reshaping how we connect with time-pressed HCPs in a fast-moving field.

JJ Mifsud

Brad Aufderheide

Cutting Through the Noise: Oncology Engagement for the Digital Era

See how AI, telemedicine, and digital screening are transforming cancer care—and why true equity demands broadband access, trust, and systemic investment.

Amy Gómez

Health Tech and the Fight for Cancer Equity: Breaking Barriers in Cancer Care

AI and automation are transforming MLR review by improving efficiency, reducing rework, and enabling compliant content reuse. Discover how to unlock speed without sacrificing accuracy.

Alfred Whitehead

Enhancing MLR Review Efficiency in Pharma Through AI and Automation

Focus groups can’t keep pace with the urgency of oncology. AI-driven simulations are changing the game—delivering insights on how oncologists respond to efficacy, safety, and competitive messaging.

Beyond Focus Groups: AI Simulation for Smarter Oncology Insights

Pharma is evolving. Explore key shifts from Pharma USA 2025, from operationalizing precision to building trust, access, and human-centric engagement.

Steve Palmieri

Smarter, Simpler, More Human: What I saw at Pharma USA 2025

In 2025, digital mediation will shape our decision-making—from healthcare to daily life. How does this impact trust, connection, and choice? Read to find out.

Meredydd Hardie

Cultural Forces 2025: Mediated Existence

Jasmine Singh, EVP Medical Strategy, Klick Health, sits down with Dr. Scott Kopetz from MD Anderson to talk about minimal residual disease and why cancer that doesn’t show up on a scan can still be a threat. They get into circulating tumor DNA, early intervention, and what’s next in colorectal cancer research.

Descubra

Stay Informed with the Klick Wire